Concord Wealth Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Concord Wealth Partners’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.42K	Buy	+200	New	+$6.07K	﹤0.01%	609
2026 Q1	–	Sell	-200	Closed	-$5.44K	–	221
2025 Q4	$5.44K	Hold	200	–	–	﹤0.01%	612
2025 Q3	$8.03K	Hold	200	–	–	﹤0.01%	563
2025 Q2	$6.65K	Hold	200	–	–	﹤0.01%	599
2025 Q1	$5.86K	Hold	200	–	–	﹤0.01%	566
2024 Q4	$6.57K	Hold	200	–	–	﹤0.01%	571
2024 Q3	$8.89K	Hold	200	–	–	﹤0.01%	566
2024 Q2	$8.62K	Hold	200	–	–	﹤0.01%	522
2024 Q1	$5.85K	Hold	200	–	–	﹤0.01%	636
2023 Q4	$4.45K	Hold	200	–	–	﹤0.01%	648
2023 Q3	$4.95K	Hold	200	–	–	﹤0.01%	719
2023 Q2	$5.66K	Hold	200	–	–	﹤0.01%	684
2023 Q1	$4.59K	Hold	200	–	–	﹤0.01%	684
2022 Q4	$5.62K	Buy	+200	New	+$5.64K	﹤0.01%	735
2022 Q3	–	Sell	-200	Closed	-$4K	–	176
2022 Q2	$4K	Hold	200	–	–	﹤0.01%	844
2022 Q1	$6K	Hold	200	–	–	﹤0.01%	858
2021 Q4	$7K	Buy	+200	New	+$8.05K	﹤0.01%	854

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Concord Wealth Partners's AGIO Position: Q2 2026 in Review

Concord Wealth Partners opened a new position in Agios Pharmaceuticals (AGIO) in Q2 2026: 200 shares worth $7.42K. The stake represents ﹤0.01% of the portfolio and ranks #609 among its holdings. This is a return to the name: Concord Wealth Partners previously reported a position in AGIO as recently as Q4 2025.

Concord Wealth Partners first reported a position in AGIO in Q4 2021 and has held it in 17 quarters since. The position peaked at $8.89K in Q3 2024. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

Concord Wealth Partners held 200 shares of Agios Pharmaceuticals worth $7.42K as of Q2 2026.
Agios Pharmaceuticals was a new Concord Wealth Partners position in Q2 2026.
Agios Pharmaceuticals made up ﹤0.01% of Concord Wealth Partners's portfolio in Q2 2026, its #609 holding.
Concord Wealth Partners first reported a position in Agios Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
Concord Wealth Partners's Agios Pharmaceuticals position peaked at $8.89K in Q3 2024.
239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Concord Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.